The Food and Drug Administration approved Relyvrio based on a trial that enrolled about 140 ALS patients and found those on the drug declined a bit slower functionally than those given placebos. The drug-treated group also lived a median of five months longer than the control arm.

There is currently no cure for ALS, a disease marked by the progressive decay of nerve cells. Even with the few therapies available, patients typically live just two to five years after symptoms start to show. There are an estimated 30,000 or so people with the disease in the U.S.

Amylyx is also trying to show its drug can provide a benefit in other brain and nervous system disorders. The company already sponsored a mid-stage clinical trial evaluating the drug as potential treatment for Alzheimer’s disease, and expects to initiate a new, late-stage study targeting progressive supranuclear palsy later this year.